Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial)

INTRODUCTION: Acute kidney injury (AKI) is a common complication after cardiac surgery (CS) and is associated with adverse short-term and long-term outcomes. Alpha-1-microglobulin (A1M) is a circulating glycoprotein with antioxidant, heme binding and mitochondrial-protective mechanisms. RMC-035 is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazer, C David, Siadati-Fini, Niloufar, Boehm, Johannes, Wirth, Felix, Myjavec, Andrej, Brown, Craig D, Koyner, Jay L, Boening, Andreas, Engelman, Daniel T, Larsson, Tobias E, Renfurm, Ronny, de Varennes, Benoit, Noiseux, Nicolas, Thielmann, Matthias, Lamy, Andre, Laflamme, Maxime, von Groote, Thilo, Ronco, Claudio, Zarbock, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Anaesthesia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410810/
https://www.ncbi.nlm.nih.gov/pubmed/37024249
http://dx.doi.org/10.1136/bmjopen-2022-068363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410810/
https://www.ncbi.nlm.nih.gov/pubmed/37024249
http://dx.doi.org/10.1136/bmjopen-2022-068363

Ejemplares similares